A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
1. Establish the MTD of Lintuzumab-Ac225 as monotherapy
2. Establish overall response rate (ORR) where ORR = CR + sCR+ VGPR+PR)
3. Confirm the safety profile of the treatment regimen
4. Estimate progression-free survival (PFS) and overall survival
Phase:
Phase 1
Details
Lead Sponsor:
Actinium Pharmaceuticals Baylor Research Institute